Hologic develops and supplies diagnostics products, medical imaging systems and surgical products focused on breast health, diagnostics, GYN surgical, and skeletal health.

Currently TCT distributes Hologic products such as ThinPrep Pap Test and related instruments, Rapid fetal Fibronectin (fFN) test and the NovaSure endometrial ablation device in China.

The present transaction also includes ThinPrep Pap Test, related instruments and other diagnostic and surgical products.

After the acquisition, the TCT business will be integrated within Hologic’s international operations.

Hologic president and CEO Rob Cascella said TCT is positioned as a national distribution presence in both the OB/GYN and laboratory markets based primarily on the strength of its sales network.

"We firmly believe by controlling a distribution channel as extensive as TCT’s, we can better leverage our entire product portfolio to drive growth across multiple market segments," Cascella said.